Relapsed or refractory diffuse large B-cell Lymphoma CAR-T Cell Therapy is superior to Standard Second-line Therapy

被引：0
|
作者：
Ruedesheim, Sabine M.
机构：
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2022年 / 45卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：231 / 231
页数：1
相关论文
共 50 条
  • [31] CAR T-cell therapy in refractory large B-cell lymphoma
    Stirrups, Robert
    LANCET ONCOLOGY, 2018, 19 (01): : E19 - E19
  • [32] NEUROTOXICITY ASSOCIATED WITH CAR-T THERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA. EXPERIENCE OF A CENTER
    Borja, Puertas
    Monica, Alana
    Lopez Estefania, Perez
    Ana Africa, Martin Lopez
    Jesus Alberto, Vizcaya
    Maria Carmen, Montes Gonzalo
    Ubeda Sandra, Gomez
    Sanchez Alberto, Hernandez
    Luz Gema, Roman Molano
    Munoz Felipe, Pena
    Mendoza Danylo, Palomino
    Laura, Prieto
    Parra Miriam, Lopez
    Pilar, Tamayo
    Gutierrez Norma, Gutierrez
    Garcia-Sancho Alejandro, Martin
    Fermin, Sanchez-Guijo
    Maria Dolores, Caballero Barrigon
    Noelia, Albala
    Corral Lucia, Lopez
    HAEMATOLOGICA, 2021, 106 (10) : 262 - 263
  • [33] Possible Factors on Efficacy and Safety of CAR-T Therapy in Relapsed or Refractory Aggressive B-Cell Lymphoma
    Huang, Haiwen
    Jiang, Yibin
    Jin, Zhengming
    Li, Caixia
    Wu, Depei
    BLOOD, 2018, 132
  • [34] Tisagenlecleucel: CAR-T Cell Therapy for B-cell Lymphoma
    Andres, Ulrike
    TRANSFUSIONSMEDIZIN, 2019, 9 (02)
  • [35] Diffuse Large B-Cell Lymphoma: Optimizing Therapy for Relapsed/Refractory Disease
    Matasar, Matthew J.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2021, 19 (11.5): : 1327 - 1330
  • [36] Assessing and Management of Neurotoxicity After CAR-T Therapy in Diffuse Large B-Cell Lymphoma
    Castaneda-Puglianini, Omar
    Chavez, Julio C.
    JOURNAL OF BLOOD MEDICINE, 2021, 12 : 775 - 783
  • [37] CAR T-Cell Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma with Progressive Muscular Dystrophy: A Case Report
    Chen, Liting
    Xu, Bin
    Liu, Wanying
    Wang, Di
    Xu, Jinhuan
    Mao, Xia
    Xiao, Min
    Zhou, Jianfeng
    Xiao, Yi
    ONCOTARGETS AND THERAPY, 2022, 15 : 361 - 366
  • [38] Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma
    Vercellino, Laetitia
    Di Blasi, Roberta
    Kanoun, Salim
    Tessoulin, Benoit
    Rossi, Cedric
    D'Aveni-Piney, Maud
    Oberic, Lucie
    Bodet-Milin, Caroline
    Bories, Pierre
    Olivier, Pierre
    Lafon, Ingrid
    Berriolo-Riedinger, Alina
    Galli, Eugenio
    Bernard, Sophie
    Rubio, Marie-Therese
    Bossard, Celine
    Meignin, Veronique
    Merlet, Pascal
    Feugier, Pierre
    Le Gouill, Steven
    Ysebaert, Loic
    Casasnovas, Olivier
    Meignan, Michel
    Chevret, Sylvie
    Thieblemont, Catherine
    BLOOD ADVANCES, 2020, 4 (22) : 5607 - 5615
  • [39] Outcomes with loncastuximab tesirine following CAR T-cell therapy in patients with relapsed or refractory diffuse large B-cell lymphoma
    Narendranath Epperla
    Melanie Lucero
    Tom Bailey
    Laura Mirams
    Jolenta Cheung
    Mona Amet
    Gary Milligan
    Lei Chen
    Blood Cancer Journal, 14 (1)
  • [40] Cost-effectiveness of second-line axicabtagene ciloleucel in relapsed refractory diffuse large B-cell lymphoma
    Kambhampati, Swetha
    Saumoy, Monica
    Schneider, Yecheskel
    Serrao, Steve
    Solaimani, Pejman
    Budde, Lihua Elizabeth
    Mei, Matthew G.
    Popplewell, Leslie L.
    Siddiqi, Tanya
    Zain, Jasmine
    Forman, Stephen J.
    Kwak, Larry W.
    Rosen, Steven T.
    Danilov, V. Alexey
    Herrera, Alex F.
    Thiruvengadam, Nikhil R.
    BLOOD, 2022, 140 (19) : 2024 - 2036
12345